- Home
- SGU vs MBX Comparison
SGU vs MBX Comparison
Compare SGU & MBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGU
- MBX
- Stock Information
- Founded
- SGU 1995
- MBX 2018
- Country
- SGU United States
- MBX United States
- Employees
- SGU N/A
- MBX N/A
- Industry
- SGU Other Specialty Stores
- MBX
- Sector
- SGU Consumer Discretionary
- MBX
- Exchange
- SGU Nasdaq
- MBX NYSE
- Market Cap
- SGU 445.9M
- MBX 379.7M
- IPO Year
- SGU 1995
- MBX 2024
- Fundamental
- Price
- SGU $11.71
- MBX $9.63
- Analyst Decision
- SGU
- MBX Strong Buy
- Analyst Count
- SGU 0
- MBX 5
- Target Price
- SGU N/A
- MBX $37.40
- AVG Volume (30 Days)
- SGU 37.8K
- MBX 227.0K
- Earning Date
- SGU 07-30-2025
- MBX 08-16-2025
- Dividend Yield
- SGU 6.30%
- MBX N/A
- EPS Growth
- SGU 123.45
- MBX N/A
- EPS
- SGU 1.78
- MBX N/A
- Revenue
- SGU $1,803,079,000.00
- MBX N/A
- Revenue This Year
- SGU N/A
- MBX N/A
- Revenue Next Year
- SGU N/A
- MBX N/A
- P/E Ratio
- SGU $6.62
- MBX N/A
- Revenue Growth
- SGU 2.38
- MBX N/A
- 52 Week Low
- SGU $10.11
- MBX $4.81
- 52 Week High
- SGU $13.75
- MBX $27.50
- Technical
- Relative Strength Index (RSI)
- SGU 40.56
- MBX N/A
- Support Level
- SGU $11.93
- MBX N/A
- Resistance Level
- SGU $11.95
- MBX N/A
- Average True Range (ATR)
- SGU 0.28
- MBX 0.00
- MACD
- SGU -0.00
- MBX 0.00
- Stochastic Oscillator
- SGU 24.42
- MBX 0.00
About SGU Star Group L.P.
Star Group LP is a company engaged in providing home heating products and services to residential and commercial customers. The company offers heating oil and air conditioning equipment, as well as home security and plumbing services. The company also sells diesel fuel, gasoline, and home heating oil. Geographically, the company operates in U.S.
About MBX MBX BIOSCIENCES INC
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.